ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 575,16
-0,70%
Dow Jones
38 834,86
0,15%
DAX
18 076,78
-0,26%
Brent Oil
84,765
-0,02%
Bitcoin
65 346,30
0,32%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pyxis Oncology Inc (PYXS)

  7. Pyxis Oncology Inc (PYXS) Actualités

PYXS Pyxis Oncology Inc

3,59
-0,07 (-1,91%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Pyxis Oncology Inc PYXS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,07 -1,91% 3,59 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,70 3,40 3,70 3,42 3,66
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
12/6/202422:17EDGAR2Form 8-K - Current report
10/6/202413:56EDGAR2Form 8-K - Current report
10/6/202413:30GLOBEPyxis Oncology Expands Board of Directors with Appointment..
07/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202413:30GLOBEPyxis Oncology to Participate in a Fireside Chat at the..
14/5/202414:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202413:55EDGAR2Form 8-K - Current report
14/5/202413:30GLOBEPyxis Oncology Provides Corporate Update and Reports..
09/5/202413:30GLOBEPyxis Oncology to Present at the RBC Capital Markets Global..
28/3/202421:30GLOBEPyxis Oncology Reports Inducement Grants Under Nasdaq..
27/3/202412:30GLOBEPyxis Oncology Obtains $8 Million Payment for the Sale of..
21/3/202412:30GLOBEPyxis Oncology Provides Corporate Update and Reports..
13/3/202413:00GLOBEPyxis Oncology Expands Board of Directors with Appointment..
08/3/202422:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07/3/202422:30GLOBEPyxis Oncology to Present at Leerink Global Biopharma..
05/3/202422:45GLOBEPyxis Oncology to Present New PYX-201, PYX-106 and PYX-102..
28/2/202413:02EDGAR2Form 8-K - Current report
27/2/202414:00GLOBEPyxis Oncology Announces $50 Million Private Placement
29/12/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202322:30GLOBEPyxis Oncology Reports Inducement Grants Under Nasdaq..
06/12/202322:50EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/11/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202313:22EDGAR2Form 8-K - Current report
28/11/202313:00GLOBEPyxis Oncology Announces Appointment of Ken Kobayashi, M.D.,..
17/11/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:44EDGAR2Form 8-K - Current report
07/11/202322:30GLOBEPyxis Oncology Announces Initiatives to Prioritize Lead ADC..
27/10/202322:34EDGAR2Form 8-K/A - Current report: [Amend]
28/9/202322:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202300:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202300:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202315:18GLOBEPyxis Oncology Announces Four Abstracts Accepted for Poster..
25/9/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202323:08EDGAR2Form 144 - Report of proposed sale of securities
31/8/202322:01GLOBEPyxis Oncology to Participate in Two Upcoming Investment..
25/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
23/8/202323:30EDGAR2Form S-8 POS - Securities to be offered to employees in..
23/8/202323:28EDGAR2Form POS AM - Post-Effective amendments for registration..
23/8/202323:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
23/8/202314:47EDGAR2Form 8-K - Current report
23/8/202314:35GLOBEPyxis Oncology Successfully Completes Acquisition of..
11/8/202323:00EDGAR2Form 144 - Report of proposed sale of securities
11/8/202313:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202313:26EDGAR2Form 425 - Prospectuses and communications, business..

Dernières Valeurs Consultées

NASDAQ
PYXS
Pyxis Oncology
BIT
P1AEQ9
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés